NEW YORK (GenomeWeb News) – Oxford Genome Sciences today said that it has changed its name to Oxford BioTherapeutics.
 
The Oxford, UK-based firm said the name change comes as it focuses its efforts on the development of its pipeline of antibody-based cancer therapeutics. The firm also has a collaboration with diagnostics firm Biosite to develop companion diagnostics for its cancer therapeutics.
 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.